Last reviewed · How we verify
Coarsucam
At a glance
| Generic name | Coarsucam |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia) (PHASE4)
- Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon (PHASE4)
- Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde (PHASE4)
- In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III) (PHASE4)
- Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon (PHASE3)
- Adherence to Antimalarial Drugs in Sierra Leone (NA)
- Dolutegravir Interactions With Artemisinin-based Combination Therapies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coarsucam CI brief — competitive landscape report
- Coarsucam updates RSS · CI watch RSS
- Sanofi portfolio CI